Article

Immune system plays an important role in the success and failure of conventional cancer therapy

Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Cancer Center, Portland, OR 97213, USA. .
Immunotherapy (Impact Factor: 2.07). 02/2012; 4(2):125-8. DOI: 10.2217/imt.11.157
Source: PubMed
0 Followers
 · 
12 Reads
  • Source
    • "Recent data demonstrates that T cells can play an important role in the efficacy of radiation therapy [17] [18], and the interplay between T cells and radiation therapy has been summarized in a number of recent reviews [16] [30] [136]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiation therapy is showing potential as a partner for immunotherapies in preclinical cancer models and early clinical studies. As has been discussed elsewhere, radiation provides debulking, antigen and adjuvant release, and inflammatory targeting of effector cells to the treatment site, thereby assisting multiple critical checkpoints in antitumor adaptive immunity. Adaptive immunity is terminated by inflammatory resolution, an active process which ensures that inflammatory damage is repaired and tissue function is restored. We discuss how radiation therapy similarly triggers inflammation followed by repair, the consequences to adaptive immune responses in the treatment site, and how the myeloid response to radiation may impact immunotherapies designed to improve control of residual cancer cells.
    Full-text · Article · Apr 2013 · Clinical and Developmental Immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is strongly influenced by the surrounding microenvironment. Cells of the immune system are critical components of this extrinsic network of cancer regulators, contributing significantly to the microenvironment of most cancers and either promoting or inhibiting the initiation and progression of this disease. Genetically engineered mouse (GEM) mouse models of spontaneous cancer are starting to shape our understanding of how antitumor T cells may act to prevent or inhibit cancer progression in some settings and not others. Lessons learned from investigating spontaneous mouse cancer models have important implications for directing clinical efforts that attempt to direct a cancer patient's immune system to eradicate their disease.
    No preview · Article · Mar 2013 · Current opinion in immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: OX40 is a member of the tumor necrosis factor (TNF) receptor family and a potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation and anti-tumor activity in patients with metastatic cancer. Ongoing investigations at our institution have demonstrated that OX40 expressing T cells are found in abundance in the tumors of patients with advanced stage head and neck squamous cell carcinoma (HNSCC). This has led to the initiation of human clinical trials investigating OX40-directed therapy for patients with HNSCC in both the metastatic and curative setting. The purpose of this review is to explore what is known about OX40 signaling and discuss how this pathway potentially can be modulated to improve outcome for patients with HNSCC.
    No preview · Article · Nov 2015